Group 1 - The core focus of the company is on the development of neurological drugs, which is identified as a key area for growth [2] - The company aims to enhance its supply chain by integrating raw material production and formulation [2] - Yichang Renfu is recognized as a leading enterprise in the neurological drug sector and serves as a benchmark for the company's development [2]

（文章来源：证券日报） 证券日报网讯 1月13日，国药现代在互动平台回答投资者提问时表示，公司一直重视科技创新与产业升 级，公司将持续关注行业发展趋势，以研发和技术驱动夯实公司核心竞争力。 ...

Group 1 - The core point of the article is that China National Pharmaceutical Group Modern (600420.SH) announced that its wholly-owned subsidiary, China National Pharmaceutical Group Weichida Pharmaceutical Co., Ltd. (referred to as Weichida), received approval from the National Medical Products Administration for a supplemental application for the injection of Piperacillin Sodium, which includes a new 1.0g specification and the approval of 0.5g, 1.0g, and 2.0g formulations through the consistency evaluation of generic drug quality and efficacy [1] Group 2 - The injection of Piperacillin Sodium is primarily used for treating infections caused by sensitive Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter species, including sepsis, upper urinary tract and complicated urinary tract infections, respiratory infections, biliary infections, abdominal infections, pelvic infections, as well as skin and soft tissue infections [1] - Piperacillin can also be used in combination with aminoglycosides for infections in patients with neutropenic immunodeficiency [1]

Core Viewpoint - The company, China National Pharmaceutical Group Modern (国药现代), announced that its wholly-owned subsidiary, China National Pharmaceutical Group Weichida Pharmaceutical Co., Ltd. (国药威奇达), received approval from the National Medical Products Administration for a supplemental application regarding the injection of Piperacillin Sodium, which includes a new 1.0g specification and the approval of 0.5g, 1.0g, and 2.0g formulations to pass the consistency evaluation of generic drug quality and efficacy [1]. Group 1 - The approval allows for the introduction of a new 1.0g specification for Piperacillin Sodium injection [1]. - The formulations of 0.5g, 1.0g, and 2.0g have successfully passed the consistency evaluation for generic drug quality and efficacy [1]. - Piperacillin Sodium is primarily used for treating infections caused by sensitive Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter species, including sepsis and various types of infections [1].

证券代码：600420 证券简称：国药现代 公告编号：2026-001 上海现代制药股份有限公司 关于全资子公司药品通过仿制药一致性评价的自愿性信息 披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，上海现代制药股份有限公司（以下简称公司）全资子公司国药集团威 奇达药业有限公司（以下简称国药威奇达）收到国家药品监督管理局核准签发的 《药品补充申请批准通知书》，批准注射用哌拉西林钠新增 1.0g 规格及本品 0.5g、 1.0g、2.0g 通过仿制药质量和疗效一致性评价（以下简称一致性评价）。现将相 关情况公告如下： 一、药品基本信息 药品名称：注射用哌拉西林钠 通知书编号：2026B00061、2026B00062、2026B00063 剂型：注射剂 药品生产企业：国药集团威奇达药业有限公司 申请事项：申请增加 1.0g（按 C₂₃H₂₇N₅O₇S 计）规格，申请本品 0.5g、1.0g、 2.0g 仿制药质量和疗效一致性评价。 审批结论：根据《中华人民共和国药品管理法》《国务院关于改革药品医疗 器械审评审批制度 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for a new specification of injectable Piperacillin Sodium and for its consistency evaluation as a generic drug [1] Group 1: Product Approval - The company's wholly-owned subsidiary, China National Pharmaceutical Group Weichida Pharmaceutical Co., Ltd., has been granted a supplement approval notice for injectable Piperacillin Sodium [1] - The newly approved specification includes 1.0g, in addition to existing 0.5g and 2.0g formulations [1] Group 2: Indications and Uses - Injectable Piperacillin Sodium is primarily indicated for infections caused by sensitive Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter species [1] - It is used to treat conditions such as sepsis, upper urinary tract and complicated urinary tract infections, respiratory infections, biliary infections, abdominal infections, pelvic infections, as well as skin and soft tissue infections [1] - The drug can also be used in combination with aminoglycosides for infections in patients with neutropenic immunodeficiency [1]

Group 1 - The animal vaccine sector experienced a decline of 0.04%, ranking among the top losers in the concept sector, with notable declines from companies such as Hengtong Co., BioShares, and Kanghua Bio [1] - Among the animal vaccine stocks, 9 companies saw price increases, with Dongfang Bio, KQ Bio, and Haili Bio leading the gains at 2.23%, 0.87%, and 0.77% respectively [1] - The sector faced a net outflow of 212 million yuan from main funds, with 14 stocks experiencing outflows, and 7 stocks seeing outflows exceeding 10 million yuan, led by Roniu Mountain with a net outflow of 82.38 million yuan [2] Group 2 - The top stocks with net outflows included BioShares, Hengtong Co., and Kanghua Bio, with net outflows of 41.91 million yuan, 41.77 million yuan, and 24.74 million yuan respectively [2] - Conversely, the stocks with the highest net inflows were Dabeinong, Haili Bio, and Guoyao Modern, with net inflows of 32.76 million yuan, 6.20 million yuan, and 3.24 million yuan respectively [2] - The trading data indicated that Roniu Mountain had a trading rate of 8.05% and a price drop of 1.05%, while Dongfang Bio had a trading rate of 1.46% and a price increase of 2.23% [3]

格隆汇1月12日丨国药现代(600420.SH)公布，近日，公司全资子公司国药集团威奇达药业有限公司收到 国家药品监督管理局核准签发的《药品补充申请批准通知书》，批准注射用哌拉西林钠新增1.0g规格及 本品0.5g、1.0g、2.0g 通过仿制药质量和疗效一致性评价。 注射用哌拉西林钠主要适用于敏感肠杆菌科细菌、铜绿假单胞菌、不动杆菌属所致的败血症、上尿路及 复杂性尿路感染、呼吸道感染、胆道感染、腹腔感染、盆腔感染以及皮肤、软组织感染等。哌拉西林与 氨基糖苷类联合应用亦可用于有粒细胞减少症免疫缺陷病人的感染。 米内网数据库显示，注射用哌拉西林钠2024年全国公立医疗机构销售额约为人民币19.06亿元。CDE网 站显示，目前注射用哌拉西林钠(0.5g，1.0g，2.0g)通过/视同通过一致性评价的企业还有山东鲁抗医药 股份有限公司、山东安信制药有限公司、华北制药（维权）集团先泰药业有限公司等。 截止目前，国药威奇达用于开展注射用哌拉西林钠一致性评价的累计研发投入约人民币612万元(未经审 计)。 ...

Core Insights - The article reports that China National Pharmaceutical Group Modern has received approval from the National Medical Products Administration for a supplemental application regarding the injectable drug Piperacillin Sodium, which now includes new specifications of 1.0g and has passed the consistency evaluation for generic drug quality and efficacy [2] Group 1 - The approval allows for the addition of new specifications (1.0g) for Piperacillin Sodium [2] - The drug is primarily used for treating infections caused by sensitive Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter species, including sepsis and complex urinary tract infections [2]

Core Viewpoint - The announcement from China National Pharmaceutical Group Modern indicates that its wholly-owned subsidiary, China National Pharmaceutical Wichida, has received notification that the injectable Piperacillin Sodium in new specifications of 1.0g, 0.5g, and 2.0g has passed the consistency evaluation for generic drugs, which is beneficial for market expansion [1] Group 1: Product Development - The new specifications for Piperacillin Sodium are applicable for various infections, with projected sales in public medical institutions in China reaching approximately 1.906 billion yuan in 2024 [1] - China National Pharmaceutical Wichida has invested approximately 6.12 million yuan in cumulative research and development for this product [1] Group 2: Market Competition - Several other companies have also had products in the same specifications pass or be deemed to have passed the consistency evaluation, indicating a competitive market landscape [1] Group 3: Market Uncertainty - While the new specifications and successful evaluations are advantageous for product market expansion, the sales of the drug are subject to various influencing factors, leading to inherent uncertainties [1]